Anthos: Novartis to Acquire for up to $3.1 Billion
Deal News | Feb 13, 2025 | Ropes & Gray
Novartis has announced its acquisition of Anthos Therapeutics, Inc. in a deal worth up to $3.1 billion. Founded by Blackstone Life Sciences and Novartis in 2019, Anthos Therapeutics holds the exclusive global rights to develop abelacimab, a significant medical innovation originally created by Novartis. Abelacimab is a novel factor XI inhibitor used for preventing stroke, systemic embolism in atrial fibrillation patients, and the recurrence of blood clots in cancer patients. The legal representation for Anthos Therapeutics, LLC, was provided by Ropes & Gray, with a team comprising mergers and acquisitions partner Michael Beauvais, mergers and acquisitions counsel Michael Connolly, and venture capital and emerging companies partner Rajarshi Banerjee. This acquisition exemplifies Novartis's continued strategic interest in expanding its role in impactful therapeutic interventions.
Sectors
- Pharmaceuticals
- Biotechnology
Geography
- United States – Anthos Therapeutics, LLC is represented by a US-based law firm, Ropes & Gray.
- Switzerland – Novartis, the acquiring company, is headquartered in Switzerland.
Industry
- Pharmaceuticals – Anthos Therapeutics and Novartis are involved in drug development and commercialization, a core aspect of the pharmaceutical industry.
- Biotechnology – The acquisition involves abelacimab, a novel factor XI inhibitor, underscoring the biotechnology component with its focus on innovative therapeutic solutions.
Financials
- $3.1 billion – The value of the acquisition deal between Novartis and Anthos Therapeutics, Inc.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Ropes & Gray | Legal Advisor | Company | An international law firm that represented Anthos Therapeutics, LLC in the acquisition deal. |
| Anthos Therapeutics, Inc. | Target Company | Company | A pharmaceutical company founded by Blackstone Life Sciences and Novartis, focused on developing abelacimab. |
| Anthos Therapeutics, LLC | Investor | Company | An investor in Anthos Therapeutics, Inc., involved in the acquisition deal. |
| Novartis | Acquiring Company | Company | A leading Swiss pharmaceutical company acquiring Anthos Therapeutics, Inc. |
| Blackstone Life Sciences | Founding Company | Company | Co-founded Anthos Therapeutics, Inc. along with Novartis. |
| Michael Beauvais | Mergers and Acquisitions Partner | Person | A partner at Ropes & Gray, involved in the legal representation of Anthos Therapeutics, LLC. |
| Michael Connolly | Mergers and Acquisitions Counsel | Person | M&A counsel at Ropes & Gray engaged in the Anthos Therapeutics acquisition. |
| Rajarshi Banerjee | Venture Capital and Emerging Companies Partner | Person | A partner at Ropes & Gray specializing in venture capital and emerging companies, involved in the transaction. |